Twist Bioscience officer sells shares for tax cover

Twist Bioscience Corp officer Dennis Cho reported a small mandated share sale linked to tax withholding.

Rhea-AI Filing Summary

Twist Bioscience Corp officer Dennis Cho reported a small mandated share sale linked to tax withholding. On May 4, 2026, he sold 1,962 shares of common stock at $57.1488 per share to cover taxes due on vesting Restricted Stock Units. After this transaction, he directly holds 135,941 shares of Twist Bioscience common stock, and the filing notes these sales were required under the company’s equity incentive plan and were not discretionary trades.

Insider Trade Summary

Net Seller: 1,962 shares

Net Sell 1 txn

Insider Cho Dennis

Role See Remarks

Sold 1,962 shs ($112K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,962	$57.1488	$112K

Holdings After Transaction: Common Stock — 135,941 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Key Figures

Shares sold: 1,962 shares Sale price per share: $57.1488 per share Shares held after transaction: 135,941 shares

3 metrics

Shares sold 1,962 shares Open-market sale on May 4, 2026 to cover tax withholding

Sale price per share $57.1488 per share Average price for the 1,962 Twist Bioscience shares sold

Shares held after transaction 135,941 shares Direct ownership of Twist Bioscience common stock after the sale

Key Terms

Restricted Stock Units, sell to cover, equity incentive plans, open-market sale

4 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

sell to cover financial

"to be funded by a "sell to cover" transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

equity incentive plans financial

"the Issuer's election under its equity incentive plans"

Equity incentive plans are company programs that pay employees, executives, or directors with company stock, stock options, or share units instead of or in addition to cash, aiming to align their interests with shareholders—like giving team members a stake in the house they help build. For investors this matters because such plans can motivate better company performance but also dilute existing ownership and increase reported compensation costs, so they affect future earnings, voting power, and share value.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Twist Bioscience (TWST) report for Dennis Cho?

Twist Bioscience reported that officer Dennis Cho sold 1,962 shares of common stock at $57.1488 per share. The filing states this transaction was required to cover tax withholding obligations tied to vesting Restricted Stock Units, not a discretionary sale.

Why did Dennis Cho’s Twist Bioscience (TWST) shares get sold?

The shares were sold to cover tax withholding obligations from vesting Restricted Stock Units. According to the filing, Twist Bioscience’s equity incentive plans mandate a “sell to cover” approach, meaning the sales were required by plan terms rather than discretionary trading.

How many Twist Bioscience (TWST) shares does Dennis Cho hold after the sale?

Following the reported transaction, Dennis Cho directly holds 135,941 shares of Twist Bioscience common stock. The sale of 1,962 shares represents a relatively small portion of his position, reflecting a routine tax-related adjustment rather than a major change in ownership.

What price did Dennis Cho’s Twist Bioscience (TWST) shares sell for in this Form 4?

The reported transaction shows 1,962 shares of Twist Bioscience common stock sold at an average price of $57.1488 per share. The filing characterizes the sale as part of a mandated “sell to cover” tax withholding process tied to Restricted Stock Unit vesting.

Does the Dennis Cho Form 4 for Twist Bioscience (TWST) indicate discretionary selling?

The Form 4 explicitly states the sale does not represent discretionary trades by Dennis Cho. Instead, the 1,962 shares were sold under Twist Bioscience’s equity incentive plans to fund required tax withholding through a “sell to cover” mechanism.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cho Dennis

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		S		1,962(1)	D	$57.1488	135,941	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

Senior Vice President, Chief Legal Officer & Corporate Secretary

	/s/ Kendra Fox, as Attorney-in-Fact for Dennis Cho	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)